(19)
(11) EP 3 890 703 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.10.2023 Bulletin 2023/41

(45) Mention of the grant of the patent:
06.09.2023 Bulletin 2023/36

(21) Application number: 19821281.3

(22) Date of filing: 04.12.2019
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 9/19(2006.01)
A61K 47/12(2006.01)
A61K 47/26(2006.01)
A61K 47/32(2006.01)
 A61K 9/08(2006.01)
A61K 47/10(2017.01)
A61K 47/18(2017.01)
A61K 31/5377(2006.01)
A61K 47/38(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0019; A61K 9/08; A61K 9/19; A61K 47/12; A61K 47/183; A61K 47/10; A61K 47/26; A61K 47/32; A61K 47/38; A61K 31/5377
(86) International application number:
PCT/IB2019/060437
(87) International publication number:
WO 2020/115676 (11.06.2020 Gazette 2020/24)

(54)

NOVEL PHARMACEUTICAL FORMULATION COMPRISING A STING MODULATOR

NEUARTIGE PHARMAZEUTISCHE FORMULIERUNG BEINHALTEND EINEN STING MODULATOR

NOUVELLE FORMULATION PHARMACEUTIQUE COMPRENANT UN MODULATEUR DU STING

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.12.2018 US 201862776102 P

(43) Date of publication of application:
13.10.2021 Bulletin 2021/41

(73) Proprietor: GlaxoSmithKline Intellectual Property Development Ltd
Stevenage SG1 2NY (GB)

(72) Inventors:
  • DHANIKULA, Anand Babu
    Collegeville, Pennsylvania 19426 (US)
  • MCQUEEN, Lisa
    Collegeville, Pennsylvania 19426 (US)

(74) Representative: Knight, Lucie Viktoria et al
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-2017/175147
   
  • SERAJUDDIN ET AL: "Salt formation to improve drug solubility", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 59, no. 7, 24 August 2007 (2007-08-24), pages 603-616, XP022211982, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2007.05.010
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).